-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Trevi Therapeutics, Maintains $23 Price Target

Benzinga·05/20/2026 17:15:19
Listen to the news
Needham analyst Serge Belanger reiterates Trevi Therapeutics (NASDAQ:TRVI) with a Buy and maintains $23 price target.